Data size not at all unusual for a Phase 2a trial. As Gary mentioned again in today's webinar - the Ph3 trial will probably looking towards 300 participants. If you look at the slide in today's presentation - the competition that did a phase 3 trial had much lower numbers than our intended Ph3 will, and two of the three barely had double the number of our Ph2!
- Forums
- ASX - By Stock
- Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis
SNT
syntara limited
Add to My Watchlist
1.72%
!
5.7¢

Data size not at all unusual for a Phase 2a trial. As Gary...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
5.7¢ |
Change
-0.001(1.72%) |
Mkt cap ! $92.62M |
Open | High | Low | Value | Volume |
5.8¢ | 5.9¢ | 5.6¢ | $174.0K | 3.073M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 83031 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 483082 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 83031 | 0.055 |
2 | 110908 | 0.054 |
4 | 394430 | 0.053 |
3 | 172230 | 0.052 |
3 | 372100 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 483082 | 1 |
0.060 | 240854 | 3 |
0.061 | 150000 | 1 |
0.062 | 125000 | 3 |
0.063 | 568340 | 2 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online